TABLE 1.
Baseline characteristics of tixagevimab/cilgavimab and control groups
| Characteristic | Tixagevimab/cilgavimab group (n = 222) | Control group (n = 222) | p value |
|---|---|---|---|
| Age (years), median (IQR) | 65 (55–72) | 64 (54–70) | .094a |
| Female sex, n (%) | 86 (39) | 92 (41) | .561b |
| Type of transplant, n (%) | .235b | ||
| Kidney | 114 (51.4) | 114 (51.4) | |
| Lung | 77 (34.7) | 70 (31.5) | |
| Liver | 17 (7.7) | 27 (12.2) | |
| Kidney/heart | 7 (3.2) | 1 (0.5) | |
| Kidney/liver | 4 (1.8) | 7 (3.2) | |
| Lung/heart | 2 (0.9) | 1 (0.5) | |
| Lung/kidney | 1 (0.5) | 1 (0.5) | |
| Pancreas/kidney | 0 (0) | 1 (0.5) | |
| Years from transplantation, median (IQR) | 3.8 (1.9–8.2) | 4.3 (2.7–7.0) | .076a |
| Number of vaccines received, n (%) | .323b | ||
| None | 2 (0.9) | 0 (0.0) | |
| One | 3 (1.4) | 0 (0.0) | |
| Two | 15 (6.8) | 20 (9.0) | |
| Three | 91 (41.0) | 91 (41.0) | |
| Four | 106 (47.7) | 107 (48.2) | |
| Five | 5 (2.3) | 4 (1.8) | |
| Months from last vaccine, median (IQR) | 2.3 (1.1–5.2) | 2.5 (0.7–5.5) | .178a |
| History of SARS-CoV-2 infection, n (%) | 15 (7) | 42 (19) | <.001b |
| History of CAD, n (%) | 55 (25) | 58 (26) | .744b |
| History of heart failure, n (%) | 50 (23) | 43 (19) | .414b |
| Tixagevimab-cilgavimab dose, n (%) | |||
| 150–150 mg | 90 (40.5) | N/A | N/A |
| 300–300 mg | 131 (59.0) | N/A | |
| 450–450 mg | 1 (0.5) | N/A |
Abbreviations: CAD, coronary artery disease; IQR, interquartile range; SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2.
a
Statistics by Mann–Whitney U-test.
b
Statistics by Pearson’s Chi-squared test.